Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kiromic BioPharma, Inc. - Common Stock (NQ:KRBP)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Kiromic BioPharma, Inc. - Common Stock

< Previous 1 2 3 Next >
Kiromic BioPharma, Inc. (NASDAQ:KRBP) Investor Notice: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 04/11/2022 -- Kiromic BioPharma, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Kiromic BioPharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Highlights
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic Biopharma Announces Filing of Form 12b-25
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Announces Changes in Management, Board of Directors
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Appoints Frank Tirelli and Dr. Karen Reeves to Company’s Board of Directors
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma, Now Clinical Stage, Reports Significant Progression Free Survival Benefit in Metastatic Pancreatic Cancer Patient Treated with KiroVax/BSK01, Company’s Phase 1 Cell Therapy Cancer Vaccine Candidate for Solid Tumors
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Announces Strategic Collaboration with Gemelli Teaching Hospital to Accelerate the Analysis of Allogeneic CAR-T Clinical Trial Candidate Alexis ISO-1 in Solid Cancers
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Announces Chief Financial Officer Transition
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Reports Second Quarter 2021 Financial Results and Operating Highlights
From Kiromic BioPharma
Via Business Wire
Kiromic Announces the Acquisition of InSilico Solutions Leveraging on Bioinformatics and Artificial Intelligence to Advance Clinical Development on Its Outpatient Allogeneic CAR-T for Solid Tumors
From Kiromic Biopharma, Inc.
Via Business Wire
Kiromic BioPharma Provides Update on IND Filings on its Off-the-Shelf, Allogeneic CAR-T for Solid Tumors
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma, Inc. Announces Closing of Public Offering
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma, Inc. Announces Pricing of Public Offering
From Kiromic BioPharma, Inc.
Via Business Wire
KRBP Presenting at 2021 Next-Gen Immuno Oncology Congress Showcasing Its Proprietary AI Targets for Off-the-Shelf Allogenic CAR-T for Solid Tumors
From Kiromic Biopharma, Inc.
Via Business Wire
KRBP Presenting at July 2021 Gamma Delta T Cell Summit to Showcase Our Off-The-Shelf Allogeneic Gamma Delta T Cell Therapy
From Kiromic Biopharma, Inc.
Via Business Wire
Kiromic Announces Expansion of In-House Cell therapy cGMP Manufacturing Facility and the Appointment of Industry Veteran Ignacio Núñez as Chief Operating and Manufacturing Officer
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic Announces FDA IND Submission First-In-Human, AI derived Off-The-Shelf IsoMesothelin Gamma Delta CAR T-cell Therapy, 30 Days Before the End of the Second Quarter
From Kiromic Biopharma, Inc.
Via Business Wire
Kiromic Announces Identification of Novel Targets for Allogeneic CAR Gamma Delta T-cell Therapy in Solid Tumors Utilizing Kiromic’s Proprietary Artificial Intelligence Engine
From Kiromic Biopharma, Inc.
Via Business Wire
Kiromic Announces FDA IND Submission Forty-Five Days before the end of the Second Quarter: First-In-Human, Off-The-Shelf Chimeric PD1 Switch Receptor - Gamma Delta T-cell Therapy
From Kiromic Biopharma, Inc.
Via Business Wire
Kiromic BioPharma Reports First Quarter 2021 Financial Results and Continued Corporate Progress
From Kiromic BioPharma
Via Business Wire
Kiromic Announces 6 Posters Presented at American Association of Cancer Research 2021 Showcasing our Artificial Intelligence (AI) Biomarker Engine
From Kiromic BioPharma, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.